How AI Is Rewriting the Biosimulation Market and the Future of Drug Development Pipelines
Drug development is expensive, slow, and risky. Biosimulation uses computational models of biological systems to predict how a drug will behave before it reaches patients, and it is becoming central to how pharma and biotech companies cut that risk. Here is what the data says about where the market stands, what is driving it, and who is shaping it.
Market Size and Growth Forecasts
According to Grand View Research, the global biosimulation market was valued at USD 4.1 billion in 2025. It is estimated at USD 4.8 billion in 2026 and projected to reach USD 14.8 billion by 2033, a CAGR of 17.3% from 2026 to 2033.
Where the growth is concentrated:
- By region: North America led with a 44.2% revenue share in 2025, and the U.S. was the largest country market. Asia Pacific is expected to grow fastest through 2033, supported by expanding CRO and CDMO activity in China, Japan, South Korea, and India.
- By product: Software led with a 59.4% share in 2025. Services is projected to grow at the fastest rate as drug development becomes more complex.
- By application: Drug development held the largest share (55.4%), while disease modeling is expected to grow fastest.
- By therapeutic area: Oncology was the largest segment, and infectious diseases is the fastest growing.
- By deployment: Cloud-based models held over 43% of the market in 2025 and are also expected to grow fastest.
- By pricing model: License-based pricing led in 2025, while subscription-based pricing is set to grow fastest.
Go Deeper! Ask Prism AI about the Global Biosimulation Market. Get instant answers to questions related to market sizing, growth drivers and their impact, and more.
Key Drivers and Technology Trends
- Regulatory support for model-informed drug development (MIDD)
Regulators are increasingly open to simulation-based evidence. Agencies such as the U.S. FDA promote PK/PD modeling, PBPK modeling, and clinical trial simulation to improve efficiency and dose selection. In January 2026, the FDA highlighted updates to its MIDD Paired Meeting Program, which lets sponsors work directly with FDA experts on simulation-based evidence. That gives pharma and biotech companies a strong reason to invest in biosimulation platforms.
- The shift toward personalized medicine
Biosimulation can model differences in genetics, physiology, and disease progression to predict how specific patient groups will respond to a therapy. Growing adoption of pharmacogenomics and precision medicine is increasing demand for platforms that combine genomic and clinical data in predictive models.
- AI and machine learning integration
This is the biggest technology opportunity. AI-enabled platforms improve predictive accuracy, automate model generation, and speed up development workflows. Two recent examples:
- In October 2025, Certara launched Certara IQ, an AI-powered quantitative systems pharmacology (QSP) platform aimed at better model reproducibility and dosing predictions.
- In October 2024, Simulations Plus and the University of Southern California secured an NIH grant to advance AI-driven drug discovery.
- Cloud and hybrid modeling
Cloud deployment lets organizations scale computing resources up or down without heavy on-premises hardware investment. Hybrid approaches, which combine mechanistic and data-driven modeling, are also gaining traction for complex biological simulations.
- Partnerships and digital twins
Collaboration is a defining feature of the industry. One example is the partnership between GNS (now Aitia) and Servier, which uses digital twin technology and causal AI to study multiple myeloma.
A challenge to watch
The main restraint is a lack of standardization. Platforms use different data formats and methods, and regulatory guidance on simulation evidence is still evolving across regions. This raises validation burdens and slows adoption, especially for small and mid-sized companies.
Have questions about the biosimulation market? Get personalized guidance on the data, segments, and forecasts behind this analysis. Speak to Analyst
Major Market Players
The competitive landscape combines established end-to-end platform providers with agile, specialized players. Companies profiled by Grand View Research include:
- Certara
- Dassault Systèmes
- Advanced Chemistry Development (now part of Revvity)
- Simulations Plus
- Schrödinger
- Chemical Computing Group
- Physiomics Plc
- Rosa & Co. LLC
- BioSimulation Consulting Inc.
- Genedata AG
- Instem
- Thermo Fisher Scientific (PPD acquired)
- Yokogawa Insilico Biotechnology
Mature vs. emerging: Certara represents the mature end of the market, with unified platforms spanning PBPK, QSP, PK/PD, and trial simulation. Its regulatory acceptance and long-standing pharma relationships create high switching costs. The trade-off is complexity and cost, which can limit uptake among smaller biotechs. Simulations Plus represents the emerging, agile end, with niche modeling specialization, cloud delivery, and academic collaborations, though with narrower global reach.
Consolidation is under way:
- November 2025: Revvity agreed to acquire ACD/Labs to strengthen its Signals software platform with AI-driven predictive capabilities.
- October 2024: Certara acquired ChemAxon to expand its cheminformatics and molecular modeling tools.
- June 2024: Simulations Plus acquired Pro-ficiency to build a more integrated drug development platform.
The Bottom Line
With regulators encouraging simulation-based evidence, AI maturing quickly, and pharma R&D under pressure to move faster, biosimulation is shifting from a supporting tool to a core part of drug development. North America remains the anchor market, but Asia Pacific’s momentum and the rise of services and subscription models point to a broader, more accessible market ahead.
U.S. Healthcare Facility Mapping & Intelligence Platform! Looking to understand the healthcare facilities behind life sciences demand? Explore the U.S. Healthcare Facility Mapping & Intelligence Platform.
- Art
- Causes
- Crafts
- Dance
- Drinks
- Film
- Fitness
- Food
- Jeux
- Gardening
- Health
- Domicile
- Literature
- Music
- Networking
- Autre
- Party
- Religion
- Shopping
- Sports
- Theater
- Wellness